LifeStance Health Group (NASDAQ:LFST) Price Target Raised to $9.00 at KeyCorp

LifeStance Health Group (NASDAQ:LFST) had its price objective raised by KeyCorp from $8.00 to $9.00 in a research report report published on Thursday,Benzinga reports. The brokerage currently has an overweight rating on the stock.

Several other research firms have also recently weighed in on LFST. UBS Group lifted their target price on LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, November 7th. BTIG Research upped their price objective on shares of LifeStance Health Group from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, February 2nd. Zacks Research downgraded shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 5th. Weiss Ratings restated a “sell (d-)” rating on shares of LifeStance Health Group in a report on Monday, December 29th. Finally, BMO Capital Markets initiated coverage on shares of LifeStance Health Group in a research note on Thursday, November 13th. They issued an “outperform” rating and a $8.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $9.67.

LifeStance Health Group Stock Down 6.1%

LFST stock opened at $6.96 on Thursday. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.58 and a quick ratio of 1.58. The firm has a market capitalization of $2.71 billion, a P/E ratio of 348.17 and a beta of 1.12. LifeStance Health Group has a 52-week low of $3.74 and a 52-week high of $8.30. The company’s 50 day simple moving average is $7.12 and its 200-day simple moving average is $6.18.

LifeStance Health Group (NASDAQ:LFST) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.02). LifeStance Health Group had a return on equity of 0.66% and a net margin of 0.68%.The firm had revenue of $382.20 million during the quarter, compared to analyst estimates of $378.51 million. During the same period in the prior year, the business posted ($0.01) EPS. The company’s revenue for the quarter was up 17.4% on a year-over-year basis. As a group, equities research analysts anticipate that LifeStance Health Group will post -0.18 EPS for the current year.

LifeStance Health Group declared that its Board of Directors has authorized a share buyback plan on Wednesday, February 25th that authorizes the company to repurchase $100.00 million in outstanding shares. This repurchase authorization authorizes the company to purchase up to 3.6% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board believes its shares are undervalued.

Insider Activity at LifeStance Health Group

In related news, insider Ann Varanakis sold 50,000 shares of the company’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $6.90, for a total transaction of $345,000.00. Following the completion of the sale, the insider directly owned 315,610 shares of the company’s stock, valued at approximately $2,177,709. This represents a 13.68% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Robert Bessler sold 119,942 shares of LifeStance Health Group stock in a transaction on Friday, December 19th. The stock was sold at an average price of $7.04, for a total transaction of $844,391.68. Following the completion of the transaction, the director owned 1,318,983 shares in the company, valued at $9,285,640.32. This trade represents a 8.34% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 270,086 shares of company stock valued at $1,891,264. Corporate insiders own 3.20% of the company’s stock.

Hedge Funds Weigh In On LifeStance Health Group

Institutional investors have recently made changes to their positions in the business. Invesco Ltd. boosted its stake in LifeStance Health Group by 6.9% during the 4th quarter. Invesco Ltd. now owns 205,486 shares of the company’s stock valued at $1,447,000 after purchasing an additional 13,177 shares during the period. Vident Advisory LLC lifted its holdings in shares of LifeStance Health Group by 148.8% during the fourth quarter. Vident Advisory LLC now owns 37,462 shares of the company’s stock worth $264,000 after buying an additional 22,406 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of LifeStance Health Group in the fourth quarter valued at approximately $96,000. Zacks Investment Management grew its stake in shares of LifeStance Health Group by 33.1% in the fourth quarter. Zacks Investment Management now owns 45,291 shares of the company’s stock worth $319,000 after acquiring an additional 11,270 shares during the last quarter. Finally, Janus Henderson Group PLC increased its position in LifeStance Health Group by 58.8% during the fourth quarter. Janus Henderson Group PLC now owns 94,500 shares of the company’s stock worth $666,000 after acquiring an additional 35,000 shares during the period. 85.50% of the stock is currently owned by institutional investors.

LifeStance Health Group News Roundup

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Company posted strong Q4 and full‑year results: Q4 revenue +17% to $382.2M, adjusted EBITDA and net income turned positive, and management guided 2026 revenue of $1.615B–$1.655B with higher EBITDA targets — bolstering growth expectations. Read More.
• Positive Sentiment: Board approved a $100M share repurchase program (up to ~3.6% of shares), signaling management confidence and potential support for the stock. Read More.
• Positive Sentiment: Multiple brokers raised price targets and ratings (UBS to $12 buy; Canaccord to $10 buy; KeyCorp to $9 overweight), reflecting improved sell‑side sentiment and providing upside anchors. Read More.
• Neutral Sentiment: Earnings were mixed: revenue and visits/clinician growth beat expectations, but GAAP EPS came in at $0.03 versus consensus ~$0.05 — the miss tempers the positive top‑line story. Read More.
• Negative Sentiment: Selling stockholders launched a secondary offering of 25M shares; LifeStance is not selling and receives no proceeds — the large potential supply increase likely pressured the share price despite company fundamentals. Read More.
• Negative Sentiment: High trading volume and reported insider/institutional selling (recent insider sales and large institutional position changes) amplify near‑term downside risk as the market absorbs both the EPS miss and the offering. Read More.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.